Top Markets
#1 Islamic Coin Islamic Coin +154.41%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +24.55%
#4 RedStone RedStone +19.62%
#5 Starpower Starpower +15.19%
#6 Lighter Lighter +12.64%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.95%
#8 SkyAI SkyAI +10.69%
#9 Monad Monad +10.55%
#10 Venom Venom +10.32%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Genenta Science S.p.A. Genenta Science S.p.A.

Genenta Science S.p.A.

GNTA
株式のランク #28068
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused... Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
株価
$1.51
最終同期: 2026-07-31
時価総額
$28.82M
変化（1日）
-0.33%
変化（1年）
-57.49%
国
IT
取引 Genenta Science S.p.A. (GNTA)

カテゴリー

Healthcare
Genenta Science S.p.A.（GNTA）のP/B比率
2026 時点のP/B比率 TTM: 0
Genenta Science S.p.A. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Genenta Science S.p.A. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH